Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Molecular Characterization of Oncostatin M-induced Growth Arrest of MCF-7 Cells Expressing a Temperature-Sensitive Mutant of p53
Authors
Cong Li
Kunju Shridhar
Jingwen Liu
Publication date
01-07-2003
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2003
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1024483017549

Other articles of this Issue 1/2003

Breast Cancer Research and Treatment 1/2003 Go to the issue

OriginalPaper

Proteomic Characterization of Nipple Aspirate Fluid: Identification of Potential Biomarkers of Breast Cancer

OriginalPaper

Quantitative Fluorescence Cytometric Measurement of Estrogen and Progesterone Receptors: Correlation with the Hormone Binding Assay

OriginalPaper

Effects of Neurotransmitters on the Chemokinesis and Chemotaxis of MDA-MB-468 Human Breast Carcinoma Cells

OriginalPaper

Tumor Necrosis Factor-α Induces Interleukin-6 Production via Extracellular-Regulated Kinase 1 Activation in Breast Cancer Cells

OriginalPaper

Breast Cancer Diagnosis by Scintimammography: A Meta-analysis and Review of the Literature

OriginalPaper

Expression of Estrogen Receptor-β in Normal Mammary and Tumor Tissues: is it Protective in Breast Carcinogenesis?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits